Insider Selling: Allogene Therapeutics Inc (NASDAQ:ALLO) Major Shareholder Sells $22,005.00 in Stock

Allogene Therapeutics Inc (NASDAQ:ALLO) major shareholder Group Holdings (Sbs) Advis Tpg sold 500 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $44.01, for a total transaction of $22,005.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Holdings (Sbs) Advis Tpg also recently made the following trade(s):

  • On Monday, June 29th, Group Holdings (Sbs) Advis Tpg sold 24,904 shares of Allogene Therapeutics stock. The stock was sold at an average price of $43.27, for a total transaction of $1,077,596.08.
  • On Wednesday, June 24th, Group Holdings (Sbs) Advis Tpg sold 15,269 shares of Allogene Therapeutics stock. The stock was sold at an average price of $43.93, for a total transaction of $670,767.17.
  • On Monday, June 22nd, Group Holdings (Sbs) Advis Tpg sold 172,425 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.83, for a total transaction of $7,384,962.75.
  • On Friday, June 19th, Group Holdings (Sbs) Advis Tpg sold 47,767 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.04, for a total transaction of $2,008,124.68.
  • On Wednesday, June 17th, Group Holdings (Sbs) Advis Tpg sold 87,319 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.18, for a total transaction of $3,683,115.42.
  • On Monday, June 15th, Group Holdings (Sbs) Advis Tpg sold 129,154 shares of Allogene Therapeutics stock. The stock was sold at an average price of $42.14, for a total transaction of $5,442,549.56.
  • On Wednesday, June 3rd, Group Holdings (Sbs) Advis Tpg sold 487,402 shares of Allogene Therapeutics stock. The stock was sold at an average price of $47.40, for a total transaction of $23,102,854.80.

NASDAQ:ALLO opened at $44.96 on Friday. The firm’s fifty day moving average is $44.68 and its 200-day moving average is $29.87. The company has a debt-to-equity ratio of 0.08, a quick ratio of 18.81 and a current ratio of 18.81. Allogene Therapeutics Inc has a 52 week low of $17.43 and a 52 week high of $55.00. The firm has a market cap of $5.34 billion, a P/E ratio of -22.59 and a beta of 1.98.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Wednesday, May 6th. The company reported ($0.58) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.58). As a group, sell-side analysts anticipate that Allogene Therapeutics Inc will post -2.27 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in ALLO. Capital Research Global Investors lifted its position in shares of Allogene Therapeutics by 37.1% during the 1st quarter. Capital Research Global Investors now owns 8,972,571 shares of the company’s stock valued at $174,427,000 after acquiring an additional 2,429,893 shares during the period. Norges Bank acquired a new position in shares of Allogene Therapeutics during the 4th quarter valued at $27,658,000. Capital International Investors lifted its position in shares of Allogene Therapeutics by 17.8% during the 1st quarter. Capital International Investors now owns 4,578,800 shares of the company’s stock valued at $89,012,000 after acquiring an additional 690,779 shares during the period. Casdin Capital LLC acquired a new position in shares of Allogene Therapeutics during the 1st quarter valued at $9,720,000. Finally, State Street Corp lifted its position in shares of Allogene Therapeutics by 25.0% during the 4th quarter. State Street Corp now owns 1,679,450 shares of the company’s stock valued at $43,632,000 after acquiring an additional 335,655 shares during the period. Institutional investors own 57.97% of the company’s stock.

A number of research firms have weighed in on ALLO. Piper Sandler boosted their target price on shares of Allogene Therapeutics from $50.00 to $70.00 and gave the stock an “overweight” rating in a report on Friday, May 29th. JMP Securities boosted their target price on shares of Allogene Therapeutics from $37.00 to $53.00 in a report on Monday, June 1st. William Blair reissued a “buy” rating on shares of Allogene Therapeutics in a report on Friday, May 29th. BidaskClub lowered shares of Allogene Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 29th. Finally, HC Wainwright reduced their target price on shares of Allogene Therapeutics from $55.00 to $49.00 and set a “buy” rating on the stock in a report on Friday, June 12th. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Allogene Therapeutics presently has an average rating of “Buy” and a consensus price target of $45.21.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?

Insider Buying and Selling by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.